FDA Approves METHYLENE BLUE — Zydus Lifesciences Limited

# FDA Approves Zydus Lifesciences' Intravenous Methylene Blue Formulation Zydus Lifesciences Limited has received FDA approval for its intravenous methylene blue formulation (ANDA215636), expanding the generic drug manufacturer's portfolio in critical care and specialty pharmaceuticals. The approval strengthens Zydus's position in the injectable generics market and provides healthcare systems with an additional sourcing option for this essential therapeutic agent.